Evidence reference only. Not medical advice, not a dosing guide, and not a recommendation to use any drug.
Echo The Echo Compendium
<- All drugs

Glucagon (endogenous Blockade)

MARKETED

glucagon (GCGR; physiology)

1
graded findings
1
effect domains
Evidence spread
High evidence 0Moderate evidence 0Low evidence 0Very low evidence 1

Glucagon (endogenous Blockade) is shown as a marketed evidence record where applicable. Findings describe observed research and regulatory records; they do not provide treatment advice.

Thin or bounded evidence here means uncertainty remains visible. It is not evidence that an effect has been ruled out.
Glucagon (endogenous Blockade) MARKETED
Appetite and food intake Increase
Very low evidence

Hepatic-portal infusion of glucagon antibodies during spontaneous meals increased meal size in ad libitum-fed rats, indicating endogenous prandial glucagon contributes...

Le Sauter J, Noh U, Geary N, Am J Physiol 1991;261(1 Pt 2):R162-165 Source
Full findingHepatic-portal infusion of glucagon antibodies during spontaneous meals increased meal size in ad libitum-fed rats, indicating endogenous prandial glucagon contributes physiologically to meal termination; the satiety action is relayed by the hepatic vagus (abolished by hepatic vagotomy in companion work).
PopulationAd libitum-fed rats
Fundingacademic/independent analysis (manufacturer not study sponsor; per-study COI not individually audited)
Scope limitsReused from corpus T9-GCGR-04 (mechanism anchor T9-GCGR-03, Geary 1993 PMID:8430871). Loss-of-function leg of the GCGR-satiety case. Human hepatic-vagal pathway not directly demonstrated.
Comparatorscontrol antibody/vehicle